MX375970B - Compuestos de triazolopirimidina y usos de los mismos. - Google Patents
Compuestos de triazolopirimidina y usos de los mismos.Info
- Publication number
- MX375970B MX375970B MX2017008529A MX2017008529A MX375970B MX 375970 B MX375970 B MX 375970B MX 2017008529 A MX2017008529 A MX 2017008529A MX 2017008529 A MX2017008529 A MX 2017008529A MX 375970 B MX375970 B MX 375970B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- triazolopyrimidine compounds
- triazolopyrimidine
- compounds
- prc2
- Prior art date
Links
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014094644 | 2014-12-23 | ||
| CN2015095320 | 2015-11-23 | ||
| PCT/IB2015/059843 WO2016103155A1 (en) | 2014-12-23 | 2015-12-21 | Triazolopyrimidine compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017008529A MX2017008529A (es) | 2017-10-25 |
| MX375970B true MX375970B (es) | 2025-03-06 |
Family
ID=55071101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008529A MX375970B (es) | 2014-12-23 | 2015-12-21 | Compuestos de triazolopirimidina y usos de los mismos. |
Country Status (40)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX375970B (es) * | 2014-12-23 | 2025-03-06 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos. |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| JP2019524872A (ja) * | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
| JP7042812B2 (ja) | 2016-06-20 | 2022-03-28 | ノバルティス アーゲー | トリアゾロピリミジン化合物の結晶形態 |
| US10689378B2 (en) | 2016-06-20 | 2020-06-23 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CN106831601A (zh) * | 2017-01-13 | 2017-06-13 | 河北博伦特药业有限公司 | 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| WO2018170290A1 (en) * | 2017-03-15 | 2018-09-20 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fmr1 expression |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| KR20190129851A (ko) * | 2017-03-16 | 2019-11-20 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도 |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| WO2019062435A1 (zh) * | 2017-09-28 | 2019-04-04 | 中国科学院上海药物研究所 | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 |
| CN109575013A (zh) * | 2017-09-28 | 2019-04-05 | 中国科学院上海药物研究所 | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| CN109867645B (zh) * | 2017-12-05 | 2021-09-14 | 中国医学科学院药物研究所 | 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法 |
| BR112020009757A2 (pt) * | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| CN109942556A (zh) * | 2017-12-21 | 2019-06-28 | 上海青煜医药科技有限公司 | 嘧啶酮化合物及其应用 |
| US11591312B2 (en) | 2018-01-23 | 2023-02-28 | Basf Se | Halogenation of pyridine derivatives |
| DK3746446T3 (da) * | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| CN110156787B (zh) * | 2018-02-13 | 2021-11-02 | 中国科学院上海药物研究所 | 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途 |
| CN110563722A (zh) * | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
| CN110734436A (zh) * | 2018-07-19 | 2020-01-31 | 上海青煜医药科技有限公司 | 嘧啶或吡嗪并环化合物及其应用 |
| WO2020108590A1 (zh) * | 2018-11-30 | 2020-06-04 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
| CN111518100A (zh) * | 2019-02-02 | 2020-08-11 | 上海青煜医药科技有限公司 | 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用 |
| IL323757A (en) * | 2019-03-15 | 2025-12-01 | Fulcrum Therapeutics Inc | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| JP7299307B2 (ja) | 2019-04-03 | 2023-06-27 | テラ・ストーン株式会社 | チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法 |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| US11814734B2 (en) | 2019-05-13 | 2023-11-14 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
| CN114269748A (zh) * | 2019-06-05 | 2022-04-01 | 米拉蒂医疗股份有限公司 | 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物 |
| WO2020247706A1 (en) * | 2019-06-05 | 2020-12-10 | Athenex, Inc. | Methods of treating and/or preventing psoriasis |
| AU2020315401B2 (en) | 2019-07-16 | 2025-05-22 | The Regents Of The University Of Michigan | Imidazopyrimidines as EED inhibitors and the use thereof |
| JP7357146B2 (ja) * | 2019-08-22 | 2023-10-05 | ブルーレイ セラピューティクス （シャンハイ） カンパニー，リミティド | アザヘテロアリール化合物及びその使用 |
| DK4034535T3 (da) * | 2019-09-26 | 2026-04-07 | Novartis Ag | Aza-quinolinforbindelser og anvendelser deraf |
| EP4056570B1 (en) * | 2019-11-01 | 2026-01-07 | ShanghaiTech University | Eed inhibitor, and preparation method therefor and use thereof |
| CN113004233B (zh) * | 2019-12-18 | 2022-12-20 | 南京优氟医药科技有限公司 | 一种用于制备prc2抑制剂的化合物、其制备方法和用途 |
| CN111333655B (zh) * | 2020-04-13 | 2021-07-13 | 武汉工程大学 | 一种三唑并嘧啶类化合物及其制备方法和应用 |
| CN113636993B (zh) * | 2020-05-11 | 2022-08-19 | 苏州亚盛药业有限公司 | (5-氟-2,3-二氢苯并呋喃-4-基)甲胺或其盐的制备方法及其中间体 |
| EP4157279A1 (en) * | 2020-05-28 | 2023-04-05 | Novartis AG | Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disorders |
| CN114907385B (zh) * | 2021-02-10 | 2026-07-21 | 上海翱路生物医药科技有限公司 | 氮杂芳基化合物、其制备方法及应用 |
| TW202312995A (zh) * | 2021-08-11 | 2023-04-01 | 大陸商上海青煜醫藥科技有限公司 | 氮雜芳基化合物、其製備方法及應用 |
| CN117384153A (zh) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | 一类甲基转移酶抑制剂及其用途 |
| WO2024215699A1 (en) * | 2023-04-11 | 2024-10-17 | Oric Pharmaceuticals, Inc. | Treatment of t-cell lymphoma |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による関節炎の治療 |
| NL1014106C2 (nl) | 2000-01-18 | 2001-07-20 | Univ Amsterdam | Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit. |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| SE519662C2 (sv) | 2001-07-04 | 2003-03-25 | Asept Int Ab | Ventilanordning vid utportioneringsanordningar |
| AU2002357667A1 (en) * | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CA2478065C (en) | 2002-03-08 | 2013-01-08 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| GB0228900D0 (en) | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
| JP2004238296A (ja) | 2003-02-04 | 2004-08-26 | Kissei Pharmaceut Co Ltd | 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20060246505A1 (en) | 2003-09-02 | 2006-11-02 | Reinhard Walther | Modulation of the synthesis of insulin |
| JP5160885B2 (ja) | 2004-06-01 | 2013-03-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US7890267B2 (en) | 2006-03-31 | 2011-02-15 | Ordway Research Institute | Prognostic and diagnostic method for cancer therapy |
| WO2008083251A2 (en) | 2006-12-27 | 2008-07-10 | Usc Stevens - University Of Southern California | Dna methylation markers based on epigenetic stem cell signatures in cancer |
| WO2009017670A2 (en) | 2007-07-26 | 2009-02-05 | University Of Massachusetts | Ras-mediated epigenetic silencing effectors and uses thereof |
| WO2009026720A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| GB0822248D0 (en) | 2008-12-05 | 2009-01-14 | Medical Res Council | Crystal meths |
| US8895526B2 (en) | 2009-03-27 | 2014-11-25 | Cold Spring Harbor Laboratory | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers |
| CN102020643A (zh) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| MX2012012966A (es) * | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| WO2012151277A1 (en) | 2011-05-02 | 2012-11-08 | Applied Informatic Solutions, Inc. | Kits and methods for selecting a treatment for ovarian cancer |
| WO2013010181A2 (en) | 2011-07-14 | 2013-01-17 | University Of Massachusetts | Methods of diagnosing cancer using epigenetic biomarkers |
| US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
| CA3177515A1 (en) | 2012-03-12 | 2013-09-19 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| JP2016500073A (ja) | 2012-11-19 | 2016-01-07 | ノバルティス アーゲー | 寄生虫病の処置のための化合物および組成物 |
| EP2934531A4 (en) | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
| HK1218930A1 (zh) | 2013-02-08 | 2017-03-17 | Abbvie Stemcentrx Llc | 新型多特异性结构 |
| PL2953941T3 (pl) | 2013-02-11 | 2017-11-30 | Constellation Pharmaceuticals, Inc. | Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania |
| EP2968565A2 (en) | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2970306A4 (en) * | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS |
| ES2919024T3 (es) | 2014-02-11 | 2022-07-21 | Mitokinin Inc | Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales |
| DK3218329T3 (en) | 2014-11-14 | 2019-04-23 | Basf Se | BENZYL PROPARGYLETHES AS NITRIFICATION INHIBITORS |
| PL3033944T3 (pl) | 2014-12-16 | 2018-07-31 | Omya International Ag | Węglan wapnia do ochrony roślin |
| MX375970B (es) * | 2014-12-23 | 2025-03-06 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos. |
| MA41272A (fr) | 2014-12-23 | 2017-10-31 | Adama Makhteshim Ltd | 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
-
2015
- 2015-12-21 MX MX2017008529A patent/MX375970B/es active IP Right Grant
- 2015-12-21 SG SG11201703880VA patent/SG11201703880VA/en unknown
- 2015-12-21 TN TN2017000204A patent/TN2017000204A1/en unknown
- 2015-12-21 PE PE2017001154A patent/PE20171307A1/es unknown
- 2015-12-21 EA EA201791420A patent/EA032416B1/ru not_active IP Right Cessation
- 2015-12-21 MY MYPI2017701623A patent/MY186837A/en unknown
- 2015-12-21 BR BR112017010354A patent/BR112017010354B8/pt active IP Right Grant
- 2015-12-21 AU AU2015370524A patent/AU2015370524B2/en not_active Ceased
- 2015-12-21 ME MEP-2019-127A patent/ME03385B/me unknown
- 2015-12-21 HR HRP20190805TT patent/HRP20190805T1/hr unknown
- 2015-12-21 CA CA2969090A patent/CA2969090C/en active Active
- 2015-12-21 JP JP2017533767A patent/JP6736559B2/ja active Active
- 2015-12-21 CR CR20170285A patent/CR20170285A/es unknown
- 2015-12-21 UA UAA201704770A patent/UA120945C2/uk unknown
- 2015-12-21 EP EP15820637.5A patent/EP3237418B1/en active Active
- 2015-12-21 UY UY0001036462A patent/UY36462A/es not_active Application Discontinuation
- 2015-12-21 RS RS20190502A patent/RS58679B1/sr unknown
- 2015-12-21 ES ES15820637T patent/ES2722048T3/es active Active
- 2015-12-21 WO PCT/IB2015/059843 patent/WO2016103155A1/en not_active Ceased
- 2015-12-21 LT LTEP15820637.5T patent/LT3237418T/lt unknown
- 2015-12-21 SI SI201530725T patent/SI3237418T1/sl unknown
- 2015-12-21 US US15/538,348 patent/US10220036B2/en active Active
- 2015-12-21 NZ NZ731664A patent/NZ731664A/en unknown
- 2015-12-21 HU HUE15820637A patent/HUE043060T2/hu unknown
- 2015-12-21 CN CN201580070691.5A patent/CN107108637B/zh active Active
- 2015-12-21 US US14/977,273 patent/US9580437B2/en active Active
- 2015-12-21 KR KR1020177016880A patent/KR102534028B1/ko active Active
- 2015-12-21 PL PL15820637T patent/PL3237418T3/pl unknown
- 2015-12-21 PT PT15820637T patent/PT3237418T/pt unknown
- 2015-12-21 DK DK15820637.5T patent/DK3237418T3/da active
- 2015-12-22 TW TW104143216A patent/TWI694076B/zh active
- 2015-12-22 JO JOP/2015/0331A patent/JO3489B1/ar active
-
2017
- 2017-05-07 IL IL252135A patent/IL252135B/en active IP Right Grant
- 2017-06-01 PH PH12017501016A patent/PH12017501016B1/en unknown
- 2017-06-16 CO CONC2017/0005992A patent/CO2017005992A2/es unknown
- 2017-06-16 CL CL2017001572A patent/CL2017001572A1/es unknown
- 2017-06-21 DO DO2017000149A patent/DOP2017000149A/es unknown
- 2017-06-23 SV SV2017005472A patent/SV2017005472A/es unknown
- 2017-06-23 GT GT201700146A patent/GT201700146A/es unknown
- 2017-07-20 EC ECIEPI201747153A patent/ECSP17047153A/es unknown
-
2019
- 2019-01-11 US US16/246,380 patent/US20190142837A1/en not_active Abandoned
- 2019-04-30 CY CY20191100456T patent/CY1121901T1/el unknown
-
2020
- 2020-04-30 US US16/863,631 patent/US11207325B2/en active Active
-
2021
- 2021-10-19 US US17/505,271 patent/US11931363B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2017000204A1 (en) | Triazolopyrimidine compounds and uses thereof | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| MX388170B (es) | Polimorfos de selinexor | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA201690268A1 (ru) | Замещенные производные хиназолин-4-она | |
| MX2016001304A (es) | Polimorfo de inhibidores de syk. | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
| CU20170007A7 (es) | Compuestos de imidazopiridazina | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| EA201600337A1 (ru) | 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний | |
| UY35274A (es) | Compuestos y métodos para tratar infecciones bacterianas | |
| CO2019001644A2 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 | |
| EA201590656A1 (ru) | Азаиндолины | |
| EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
| EA201600002A1 (ru) | Производные пролекарства замещенных триазолопиридинов | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam | |
| CL2017000242A1 (es) | Compuestos de imidazopiridazina | |
| GT201500232A (es) | Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |